Pyruvate kinase deficiency causes lifelong hemolytic anemia managed with transfusions and splenectomy, neither of which corrects the underlying enzyme defect. Pyrukynd (mitapivat) was the first therapy to do so.
As an allosteric activator of the pyruvate kinase enzyme, it restores glycolytic ATP production in red blood cells, improving their stability and survival rather than only replacing lost cells. The twice-daily tablet treats hemolytic anemia in adults with pyruvate kinase deficiency.
Pyrukynd holds orphan designation with no generic competition and is the first disease-modifying therapy in the indication. Mitapivat’s development in thalassemia and sickle cell disease is the main value driver to track, as those populations dwarf the approved one.
